KNIGHT THERAPEUTICS
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 under the symbol GUD.
KNIGHT THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1995-01-01
Address:
Westmount, Quebec, Canada
Country:
Canada
Website Url:
http://www.gud-knight.com
Total Employee:
101+
Status:
Active
Contact:
(514) 484-4483
Total Funding:
490.01 M USD
Technology used in webpage:
SPF LetsEncrypt Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS GoDaddy DNS Google Maps API Imperva Bot Detection And Mitigation Incapsula
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Jonathan Ross Goodman Founder ,President & CEO @ Knight Therapeutics
Founder ,President & CEO
2014-02-01
Samira Sakhia President, Chief Executive Officer & Director @ Knight Therapeutics
President, Chief Executive Officer & Director
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-10-21 | Grupo Biotoscana SL | Grupo Biotoscana SL acquired by Knight Therapeutics | 281 M USD |
Investors List
Long Zone Holdings
Long Zone Holdings investment in Post-IPO Equity - Knight Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2017-08-10 | Synergy CHC | Knight Therapeutics investment in Post-IPO Debt - Synergy CHC | 10 M USD |
| 2016-01-25 | INTEGA Skin Sciences | Knight Therapeutics investment in Debt Financing - INTEGA Skin Sciences | 12.3 M CAD |
| 2015-08-26 | Advaxis | Knight Therapeutics investment in Post-IPO Equity - Advaxis | 25 M USD |
| 2015-04-30 | Profound Medical Inc | Knight Therapeutics investment in Venture Round - Profound Medical Inc | 28 M CAD |
Official Site Inspections
http://www.gud-knight.com Semrush global rank: 5.72 M Semrush visits lastest month: 1.47 K
- Host name: edge.redirect.pizza
- IP address: 89.106.200.1
- Location: Luxembourg
- Latitude: 49.7498
- Longitude: 6.1661
- Timezone: Europe/Luxembourg
More informations about "Knight Therapeutics"
Knight Therapeutics - Wikipedia
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange (symbol GUD), with a market capitalization of $1.02 billion as of August 2019. See details»
CORPORATE PROFILE OUR FOOTPRINT - Knight Therapeutics
Knight Therapeutics Inc. (TSX: GUD), founded in 2014 by Jonathan Ross Goodman (co-founder of Paladin Labs Inc.), is a pan-American (ex-USA) specialty pharmaceutical company focused …See details»
Knight Therapeutics Inc. (GUD.TO) - Yahoo Finance Canada
Find the latest Knight Therapeutics Inc. (GUD.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Knight Therapeutics Inc. …See details»
Knight Therapeutics Inc. (TSX: GUD) - Stock Analysis
2 days ago Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico. MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) …See details»
Knight Therapeutics Announces Leadership Change
Knight Therapeutics Inc. Samira Sakhia President and Chief Operating Officer T: 514-484-4483 F: 514-481-4116 info@knighttx.com www.gud-knight.com: Arvind UtchanahSee details»
Knight Therapeutics Inc. (TSX: GUD) Company Profile & Overview
Nov 6, 2024 Ticker Symbol: GUD: Exchange: Toronto Stock Exchange: Fiscal Year: January - December: Reporting Currency: CAD: ISIN Number: CA4990531069: SIC Code: 2834See details»
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 …
Mar 21, 2024 Achieved Record Annual Revenues and EBITDA MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a …See details»
GUD | Knight Therapeutics Inc. Profile | MarketWatch
Knight Therapeutics Inc. company facts, information and financial ratios from MarketWatch. ... GUD Profile. Company Profile. Knight Therapeutics Inc. 3400 de Maisonneuve West. Suite 1055.See details»
Knight Therapeutics Inc (GUD-T) Profile - The Globe and Mail
Oct 25, 2001 Knight Therapeutics Inc 3400 De Maisonneuve West Suite 1055 Montreal QC H3Z 3B8 CAN P: 514-484-4483 F: 514-481-4116 https://www.gud-knight.comSee details»
Knight Therapeutics Announces Leadership Change - Yahoo Finance
May 13, 2021 Investor Contact: Knight Therapeutics Inc.Samira SakhiaPresident and Chief Operating OfficerT: 514-484-4483F: 514-481-4116info@knighttx.com www.gud …See details»
TSX:GUD (Knight Therapeutics Inc.) - The Motley Fool Canada
TSX:GUD (Knight Therapeutics Inc.) About GUD. Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on …See details»
Knight Therapeutics Inc. places No. 22 on The Globe and
Sep 23, 2022 Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud …See details»
Knight Therapeutics Management - Simply Wall St
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34% Mar 02. New 90-day low: CA$5.16 Feb 27. Knight Therapeutics Inc., Annual …See details»
Knight Therapeutics - Funding, Financials, Valuation & Investors
Knight Therapeutics is registered under the ticker TSX:GUD . Knight Therapeutics is funded by 3 investors. International Finance Corporation and Long Zone Holdings are the most recent …See details»
Knight Therapeutics Announces Leadership Change | INN
May 12, 2021 Knight Therapeutics Inc. Samira Sakhia President and Chief Operating Officer T: 514-484-4483 F: 514-481-4116 info@knighttx.com www.gud-knight.com Arvind Utchanah …See details»
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's …
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report …See details»
Knight Therapeutics Inc. (GUD.TO) - Yahoo Finance Canada
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- …See details»
(GUD) Strategic Investment Guide
Jan 10, 2025 This strategic investment guide for Knight Therapeutics Inc. (TSX: GUD) is powered by Stock Traders Daily's AI, developed over 20 years to identify the best trading …See details»
Knight Therapeutics Inc. (TSX: GUD) Historical Stock Price Data
Jan 10, 2025 Get a complete stock price history for TSX: GUD (Knight Therapeutics), starting from its first trading day. Includes open, high, low, close and volume.See details»